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tZorticosteroids have previously been reported to partially inhibit the natural cytotoxic activity of peripheral blood lymphocytes. I-Iowever, since 
onIy a few percent of peripheral Iymphocytes are natural killer (NK) cells, it has not been possible to determine whether corticosteroids directly 
inhibit NK cells or mediate this effect via other cell types. This report documents direct functional inactivation, but unimpeded proliferation, of 
cloned human NK cells by subphysiologic levels of cortisol. In contrast, high concentrations of testosterone, progesterone or estradiol had no signifi- 
cI-bt effect on proliferation or cytotoxic activity of the cloned NK cells. The kinetics of inhibition of NK function by cortisol are consistent with 
a transcription-dependent mechanism. 
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1. INTRODUCTION 
Corticosteroids are known to affect a number of im- 
mune functions and are used for the treatment of 
several autoimmune diseases [l-3]. A large body of 
evidence supports the involvement of natural killer cells 
in immune surveillance against viruses and tumors, and 
possibly in the pathogenesis of some autoimmune 
diseases [4]. Recently, interleukin-2 (IL-2), has been us- 
ed to generate lymphokine-activated killer (LAK) cells 
[5,6], which include activated NK cells [4], and which 
may have significant potential for immunotherapy of 
cancer and other diseases [7]. A number of previous 
reports have indicated that the natural cytotoxic activity 
of human peripheral blood lymphocytes is inhibited in 
vitro or in vivo by natural [8,9] or synthetic [lo] 
glucocorticoids. A recent study indicates that LAK cells 
are less sensitive to inhibition by glucocorticoids than 
are unactivated NK cells with respect to their cytolytic 
activities [ll]. However, due to the low frequency of 
NK cells in human peripheral blood (about 3070), and 
the heterogeneity of lymphocytes comprising LAK cell 
populations, it has not been possible thus far to deter- 
mine whether glucocorticoids act directly on NK cells or 
inhibit their function indirectly by inducing another cell 
type to produce a secondary mediator [lo], 
[l&13] now permits the systematic characterization of 
NK cells and their mechanism of action [ 141. In the pre- 
sent work, the effects of cortisol on the proliferation 
and cytotoxic activity on this human NK clone were in- 
vestigated. Additional naturally occurring steroids were 
also examined to determine the specificity of the 
observed inhibition. The dependence of NK function on 
the concentration of cortisol and the kinetics of 
cortisol-dependent inhibition were also determined. 
The results obtained strongly support a primary role for 
cortisol in the regulation of NK cells and demonstrate 
the utility of this cell line for further characterization of 
the mechanism of NK regulation by glucocorticoids. 
2. MATERIALS AND METMODS 
Cortisol. testosterone, progesterone and estradiol were purchased 
from Sigma (St. Louis). Fetal bovine serum with low cortisol content 
(5.52 nM ) was obtained from Hyclone (Logan, Utah) and 
Lymphocult-T (crude T cell growth factor) from BioTest (Dreieich, 
Germany). 
2. I, Narura! killer ceils 
The availability of a cloned human NK cell line 
Correspondence address: D.M. Callewaert, Institute for 
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The cloned human NK cell line designated NK3.3 was generously 
provided by Dr J. Kornbluth (U. Arkansas). The NK3.3 clone has a 
unique cell surface phenotype, CD2 + , CD3-.CD4-, CD5-,CD8- 
CD16’. CD38’, CD45’, HLA-DR’, DP+, DQ’, Leu7- that 
distinguishes it from mature T cells, monocytes and other lymphocyte 
populations [12]. It has also recently been shown that NK3.3 cells do 
not produce functional transcripts for the (Y, 0, or y chains of the T 
cell receptor [13]. NK3.3 cells were maintained in continuous culture 
at 3 x 10’ to 1 x IO6 cells/ml in RPMI-1640 medium supplemented 
with 20% fetal bovine serum (Hyclone) from a lot selected for low 
corticosteroid content (less than 1 &dl) and 2OYo IL-2 (Lymphocult- 
T, BioTesr) medium. Viable NK3.3 cells were counted every 48 h, cen- 
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Fig. 1. Dose-response curve for the inactivation of cytotoxic function 
of NK3.3 cells cultured for G days in medium supplemented with cor- 
tisol. 
trifuged, the used medium decanted and the cells resuspended at I X 
IO6 cells/ml in fresh medium. Cytotoxicity assays were performed 
18-20 h after addition of fresh medium. 
2.2. Torgel cells 
The K-562 cell line, derived from a patient with myelogenous 
leukemia 1151 was maintained in RPMI-1640 medium containing 25 
mM bicarbonate, and 10% fetal bovine serum (RPMI-FBS). On the 
day of an experiment, an aliquot of K-562 cells was removed from 
culture, centrifuged (150 x g for 10 min) and resuspended in 0.5 ml 
of medium. Subsequently, 250 pCi of sodium chromate (“Cr, New 
England Nuclear, Boston, MA) were added. After incubation for I 11 
at 37°C. the cells were washed 3 times with cold RPMI-FBS’medium 
and resuspended in that medium. Viable cells were enumerated with 
Trypan blue, and diluted to the concentrations desired for the experi- 
ment. 
Cytotoxicity assays were performed using a previously described 
method [16]. Briefly, various concentrations of “Cr-labeled target 
cells (I x IO’ to 1 x 10” viable cells in 0.1 ml) and a fixed concentra- 
tion of NK3.3 cells (generally I x IO’ in 0.1 ml) were added to wells 
of conical-bottomed microtiter plates. The plates were then centrifug- 
ed (150 x g for 5 min at 25°C) and incubated at 37°C in an at- 
mospherc of 95vo air and 5% CO2 for 2 h. Cytotosicity was ter- 
minated by addition of 0.05 ml of ice cold RPMI-FBS toeach well and 
the plates centrifuged (1000 x g for 5 min at 5°C). An equal aliquot 
of supernatant was then removed from each well and counted on a 
gamma counter. Spontaneous release of “Cr was determined by in- 
cubation of K-562 cells in 0.15 ml of RPMI-FBS without added effec- 
tor cells, and masimal “Cr-release was achieved by sonication of an 
aliquot of K-562 target cells. All reactions and controls wcrc perform- 
ed in triplicate. Specific activity values (the number of target cells lys- 
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Fig. 2. Kinetics of inactivation of the cytotoxic function of NK3.3 
cells by cortisol. The relative cytotoxic activity for K-562 target cells 
of NK3.3 cells in medium supplemented with 100 &I was compared 
to control cells cultured in the standard low cortiso! medium. Error 
bars represent 90% confidence intervals. 
ed per hour per 100 NK3.3 cells) were calculated by a distribution-free 
procedure that has been published [17.18], 
3. RESULTS 
The dose-dependent inactivation of the cytotoxic ac- 
tivity of cloned NK3.3 cells cultured in medium sup- 
plemented with cortisol is shown in Fig. 1. Comparable 
results were obtained in several experiments, and 
80-100% inactivation of cytotoxic function was achieti- 
ed by culture of NK3.3 cells for 8-10 days in medium 
supplemented with O.Ol- 1.6 PM cortisol. 
The results of experiments to determine the specifici- 
ty of inactivation of cytotoxic function by steroids are 
summarized in Table I. NK3.3 cells were cultured for 10 
days at equal concentrations (2 PM) of the indicated 
steroids. As shown in Table I, cortisol rapidly and corn- 
pletely inactivates NK3.3 function. Culture of NK3.3 
cells in the presence of the other steroids, at a concen- 
tration that is two orders of magnitude higher than the 
concentration of cortisol required for 100% inactiva- 
tion of NK3.3 cells, did not significantly alter the 
cytotoxic activity of this NK clone. 
The kinetics of inactivation of this NK clone by cor- 
Table 1 
Effect of steroid hormones on the cylotoxic activity and proliferation of cloned human NK cells 
Steroid Cytotoxic Activity Proliferation 
8 days 
Control 
3 Days 
58.9 (56.1-61.9) 
8 Days 
38.7 (35.8-42.6) 84 533.47 k 8222.97 
Cortisol 3.3 (1.6-13.2). 0.0 i - 12.1-2.8) 75 814.87k7331.44 
Testosterone 40.9 (38.2-44.6) 36.6 (34.2-39.4) 70 524.60 -t- I I 474.5 I 
Progesterone 64.2 (60.7-69.8) 28.8 (24-l-34.6) 57 608.53 -e 5562.20 
Estradiol 63.5 (60.8-66.9) 28.1 (25.3-31.7) 99 671.57k9722.49 
Cytotoxic activity and proliferation of cloned NK3.3 cells were measured at 2 time intervals after subculture in the presence of 0.57 &ml of the 
indicated steroids. The 90% confidence intervals for the specific activity values are given in parentheses. Proliferation was measured as 
[‘Hlrhymidine uptake in 18 h by I x IO’ cells. Mean uptake I+ SD of triplicate cultures is presented. 
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tisol are presented in Fig. 2. Although incubation in the 
presence of cortisol inhibits over 50% of the NK activity 
within 24 h, complete inactivation requires more than 
72 h of continuous exposure to cortisol. Transfer of 
cortisol-inactivated NK3.3 cells to standard medium 
(containing 1.1 nM cortisol derived from the FBS) 
resulted in gradual recovery of cytotoxic function (data 
not shown). 
4. DISCIJSSION 
The experiments in this report document that con- 
tinuous culture of cloned human NK cells in the 
presence cortisol, even at concentrations as low as 20 
nM, result in complete inactivation of their cytotoxic 
activity. This inhibition was specific for cortisol and, 
since the normal physiologic level of cortisol in human 
serum ranges from 140 to 400 nM [19], these results in- 
dicate that the cytotoxic activity of NK cells may be 
greatly suppressed by cortisol in normal individuals. 
This hypothesis is supported by previous reports that 
fresh human NK ceils are inactivated by culture in 
medium supplemented with human serum [20], but that 
NK activity generally increases upon sulture of human 
lymphocytes in medium supplemented with fetal bovine 
serum [21]. The cortisol concentration of media sup- 
plemented with lo-20% FBS can range from < 1 to 2 
nM, which causes little or no inactivation of NK func- 
tion (see Fig. I). 
In vivo administration of IL-2 produces a transient 
increase in the activity of cytotoxic cells [22,23], but II-2 
therapy alone is generally ineffective for in vivo therapy 
of tumors [22-241. In contrast, ex vivo culture of lym- 
phocytes in media supplemented with II-2 gives rise to 
highly active LAK cells [5,6,213 which, in combination 
with IL-2, have shown some clinical utility (see [25,26]). 
Based on the results reported herein, it is possible that 
the relatively poor clinical response to therapy with IL-2 
alone is at least partly due to inhibition of cytotoxic 
function by physiologic levels of cortisol. In fact, IL-2 
administration has been reported to increase serum cor- 
tisol levels [24]. The recent report by Imir et al. [l l] that 
incubation of human LAK cells for up to 72 h with 
10-“-10-9 M dexamethasone resulted in little or no in- 
hibition of cytotoxic function is in marked contrast to 
glucocorticoid inhibition of fresh NK cells [S-IQ] or 
cloned human NK cells documented herein, and should 
be investigated further. Piccollella et al. [27] have pro- 
posed that dexamethasone inhibits development of NK 
ceils by inhibiting IL-2 receptor expression. The ability 
of IL-2 dependent NK3.3 cells to propagate for several 
weeks in medium containing high concentrations of 
cortisol does not support an inactivation mechanism 
based on altered expression of the IL-2 receptor. 
The NK3.3 cell line, whose cytotoxic function can be 
reversibly inactivated by subphysiologic concentrations 
of cortisol without toxicity or reduction in proliferative 
110 
capacity, should serve as an excellent model for elucida- 
tion of the molecular basis of the cortisol-dependent in- 
activation of cellular sytotoxic function. Further 
studies with this cloned human cell line may also form 
the basis for development of improved protocols for 
immunotherapy of cancer and other diseases. 
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